vimarsana.com

Latest Breaking News On - Agency seeking approval of lazertinib - Page 1 : vimarsana.com

Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer -December 21, 2023 at 08:44 am EST

News Release Media Contacts: Zayn Qureshi +44 7760 334666 Email: zqureshi@its.jnj.com Investor.

Region flamandeUnited statesCatherine taylorKiran patelZayn qureshiJanssen research developmentJanssen biotech incEuropean unionJanssen pharmaceutical companies of johnsonClinical developmentNational cancer instituteAmerican lung associationEuropean society of medical oncologyJanssen researchEuropean medicines agencyCilag gmbh international

vimarsana © 2020. All Rights Reserved.